Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Evaxion Biotech ( (EVAX) ).
On May 7, 2026, Evaxion reported a strong operational start to the year, highlighting new data showing its AI-Immunology platform correctly identified vaccine targets in 86% of cases for its EVX-01 personalized melanoma vaccine and confirming scalability into glioblastoma, while also advancing next-generation polio vaccine concepts with The Gates Foundation and completing a one-year extension of its phase 2 EVX-01 trial. The company optimized its leadership team, remained engaged in multiple partnership discussions, and, despite widening its quarterly net loss to $3.6 million on lower finance income and zero revenue, maintained a cash position of $18.4 million and reiterated a funding runway into the second half of 2027, underscoring both its capital needs and its growing scientific validation in AI-driven vaccine development.
Evaxion’s first-quarter 2026 financials showed operating expenses broadly stable, with R&D spending inching up as programs progressed and G&A costs declining on reduced capital market expenses, while total equity fell to $13.2 million from $17.0 million at year-end 2025. Management framed the latest clinical and platform data, particularly around EVX-01’s precision and the glioblastoma findings, as key assets in ongoing business development efforts and future strategic collaborations, potentially strengthening the company’s position in the competitive AI-enabled immunotherapy space.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Copenhagen-based, clinical-stage TechBio company listed on Nasdaq that develops novel cancer and infectious disease vaccines using its proprietary AI-Immunology platform. The company’s pipeline includes the personalized cancer vaccine EVX-01 for advanced melanoma and vaccine design programs in high-need indications such as glioblastoma and polio, with a strategy centered on partnerships and platform validation.
Average Trading Volume: 30,067
Technical Sentiment Signal: Hold
Current Market Cap: $36.78M
See more data about EVAX stock on TipRanks’ Stock Analysis page.